OBiO Technology (Shanghai) Corp. Ltd. A
688238 · SHG · Healthcare / Biotechnology
Price History
Full chartMarket Stats
About
Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China and internationally. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products, as well as engages in the production and sales of biological raw materials, biological agents, reagents, and other products. The company was formerly known as Obio Technology (Shanghai) Corp., Ltd. and change its name to Shanghai Obio Technology (Group) Corp., Ltd. in March 2026. The company was founded in 2013 and is headquartered in Shanghai, China.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Oudong Pan
- Employees723
- HeadquartersInternational Medical Park, Shanghai, China, 201321, China
- Websitehttps://www.obiosh.com
Leadership
- Mr. Oudong PanFounder & Chairman of the Board · b. 1968
- Mr. Junyi PanGM & Director · b. 1994
- Ms. Luyuan XuDeputy GM, Accounting Supervisor & Board Secretary · b. 1970
- Ms. Shan YinDeputy GM & Director · b. 1982
- Ms. Qingmei XiaDeputy General Manager · b. 1979
- Ms. Qinbin WuDeputy General Manager · b. 1972
- Ms. Jiali YangDeputy Director of R&D · b. 1986
- Mr. Houliang WeiVice President of Process Development · b. 1988
- Mr. Haizi ChengTechnical R&D Director · b. 1984
- Ms. Suli LiuCDMO Project Manager · b. 1984
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Stock Splits
- May 30, 20231.3:1